Drugs by condition
Drugs approved for non-small cell lung cancer
Last checked: Nov 20, 2026Source: FDA labels (openFDA), Drugs@FDAMethods & limitations
Brand-name drugs approved
75
Still marketed, NDA or BLA
Drug classes
10
Novel drugs
43
New molecular entities and new biologics
In development
40+
Investigational drugs in Phase 2 or 3
Newest approvals
The most recently first-approved brand-name drugs for non-small cell lung cancer.
- Jideytro (Zidesamtinib) · Nuvalent NovelOrphanJul 22, 2026
- Rybrevant Faspro (Amivantamab and Hyaluronidase-Lpuj) · Janssen Biotech Priority reviewDec 17, 2025
- Hyrnuo (Sevabertinib) · Bayer Healthcare NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanNov 19, 2025
- Keytruda Qlex (Pembrolizumab, Berahyaluronidase Alfa-Pmph) · Merck Sharp Dohme NovelAccelerated approvalPriority reviewSep 19, 2025
- Hernexeos (Zongertinib) · Boehringer Ingelheim NovelBreakthrough therapyAccelerated approvalPriority reviewAug 8, 2025
All approved drugs for non-small cell lung cancer, by class
Every marketed NDA or BLA whose current FDA label names this condition in its Indications and Usage section, plus 59 generic labels. A drug can be approved for only part of a condition (one subtype or stage, or as add-on therapy), so check its label.
Kinase Inhibitor (14)
- Hernexeos Zongertinib · Boehringer Ingelheim · 2025
- Lazcluze Lazertinib Mesylate · Janssen Biotech · 2024
- Augtyro Repotrectinib · Bristol · 2023
- Gavreto Pralsetinib · Rigel Pharms · 2020
- Retevmo Selpercatinib · Eli Lilly and CO · 2020
- Lorbrena Lorlatinib · Pfizer · 2018
- Alunbrig Brigatinib · Takeda Pharms USA · 2017
- Tagrisso Osimertinib Mesylate · Astrazeneca · 2015
- Gilotrif Afatinib Dimaleate · Boehringer Ingelheim · 2013
- Xalkori Crizotinib · Pf Prism Cv · 2011
- Retevmo Selpercatinib · Eli Lilly and CO · 2024
- Xalkori Crizotinib · Pf Prism Cv · 2023
- Zykadia Ceritinib · Novartis · 2019
- Iressa Gefitinib · Astrazeneca · 2015
Vascular Endothelial Growth Factor Inhibitor (6)
Microtubule Inhibitor (6)
- Beizray Docetaxel · Zhuhai · 2024
- Paclitaxel Paclitaxel · Teva Pharms INC · 2023
- Paclitaxel Paclitaxel · Am Regent · 2022
- Docetaxel Docetaxel · Accord Hlthcare · 2011
- Docetaxel Docetaxel · Hospira INC · 2011
- Abraxane Paclitaxel · Bristol-Myers · 2005
Programmed Death Receptor-1 Blocking Antibody (4)
- Tecentriq Atezolizumab · Genentech INC · 2016
- Opdivo Nivolumab · Bristol Myers Squibb · 2014
- Keytruda Pembrolizumab · Merck Sharp Dohme · 2014
- Tecentriq Hybreza Atezolizumab and Hyaluronidase-Tqjs · Genentech INC · 2024
Endoglycosidase (3)
- Keytruda Qlex Pembrolizumab, Berahyaluronidase Alfa-Pmph · Merck Sharp Dohme · 2025
- Rybrevant Faspro Amivantamab and Hyaluronidase-Lpuj · Janssen Biotech · 2025
- Opdivo Qvantig Nivolumab, Hyaluronidase-Nvhy · Bristol-Myers Squibb · 2024
CTLA-4-directed Blocking Antibody (2)
Programmed Death Ligand-1 Blocker (1)
- Imfinzi Durvalumab · Astrazeneca Uk LTD · 2017
Vascular Endothelial Growth Factor Receptor 2 Antagonist (1)
- Cyramza Ramucirumab · Eli Lilly and CO · 2014
Folate Analog Metabolic Inhibitor (1)
- Axtle Pemetrexed Dipotassium · Avyxa Holdings · 2024
Class not listed in FDA's data (37)
- Jideytro Zidesamtinib · Nuvalent · 2026
- Hyrnuo Sevabertinib · Bayer Healthcare · 2025
- Zegfrovy Sunvozertinib · Dizal · 2025
- Ibtrozi Taletrectinib Adipate · Nuvation · 2025
- Emrelis Telisotuzumab Vedotin-Tllv · Abbvie INC · 2025
- Datroway Datopotamab Deruxtecan-Dlnk · Daiichi Sankyo INC · 2025
- Ensacove Ensartinib Hydrochloride · Xcovery · 2024
- Bizengri Zenocutuzumab-Zbco · Merus N.V. · 2024
- Krazati Adagrasib · Bristol · 2022
- Lumakras Sotorasib · Amgen INC · 2021
- Rybrevant Amivantamab-Vmjw · Janssen Biotech · 2021
- Tepmetko Tepotinib Hydrochloride · Emd Serono INC · 2021
- Tabrecta Capmatinib Hydrochloride · Novartis Pharm · 2020
- Enhertu Fam-Trastuzumab Deruxtecan-Nxki · Daiichi Sankyo · 2019
- Rozlytrek Entrectinib · Genentech INC · 2019
- Libtayo Cemiplimab-Rwlc · Regeneron Pharmaceuticals · 2018
- Braftovi Encorafenib · Array Biopharma INC · 2018
- Mektovi Binimetinib · Array Biopharma INC · 2018
- Alecensa Alectinib Hydrochloride · Hoffmann-La Roche · 2015
- Tafinlar Dabrafenib Mesylate · Novartis · 2013
- Mekinist Trametinib Dimethyl Sulfoxide · Novartis · 2013
- Alimta Pemetrexed Disodium · Lilly · 2004
- Taxotere Docetaxel · Sanofi Aventis US · 1996
- Photofrin Porfimer Sodium · Pinnacle Biolgs · 1995
- Avgemsi Gemcitabine Hydrochloride · Avyxa Holdings · 2025
- Rozlytrek Entrectinib · Genentech INC · 2023
- Pemetrexed Pemetrexed Disodium · Shilpa · 2023
- Mekinist Trametinib, Trametinib Dimethyl Sulfoxide · Novartis · 2023
- Tafinlar Dabrafenib Mesylate · Novartis · 2023
- Docetaxel Docetaxel · Avyxa Holdings · 2022
- Pemetrexed Disodium Pemetrexed Disodium · Hospira · 2022
- Pemetrexed Disodium Pemetrexed Disodium · Sandoz · 2022
- Pemetrexed Pemetrexed · Actavis · 2020
- Pemfexy Pemetrexed · Eagle Pharms · 2020
- Docetaxel Docetaxel · Actavis · 2013
- Gemcitabine Hydrochloride Gemcitabine Hydrochloride · Hospira INC · 2011
- Docetaxel Docetaxel · Sandoz · 2011
Drugs in development for non-small cell lung cancer
Investigational drugs FDA has not approved, in active or recent industry-sponsored Phase 2 and 3 trials for this condition. Phase 3 first.
- SKB264MK-2870, Sacituzumab TirumotecanPhase 353 trials
Merck & Co. · Non-Small Cell Lung Cancer, Non-small Cell Lung Cancer, Cervical Cancer
- BMS-986507BL-B01D1, Iza-brenPhase 351 trials
Sichuan Baili Pharmaceutical Co., Ltd. · Non-small Cell Lung Cancer, Solid Tumor, Urothelial Carcinoma
- IvonescimabAK112, SMT112Phase 349 trials
Akeso · Non-Small Cell Lung Cancer, Advanced Malignant Tumors, Advanced Solid Tumors
- AdebrelimabSHR-8068, HRS -4642Phase 341 trials
Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Non-small Cell Lung Cancer, Advanced or Metastatic Non-small Cell Lung Cancer, Advanced Solid Tumors
- RilvegostomigAZD2936Phase 325 trials
AstraZeneca · Biliary Tract Cancer, Gastric Cancer, Non-small Cell Lung Cancer
- SerplulimabHLX10, HLX43Phase 325 trials
Shanghai Henlius Biotech · Non Small Cell Lung Cancer, Carcinoma, Hepatocellular, SCLC, Extensive Stage
- AdabelimumabSHR-A2102, SHR2554Phase 320 trials
Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Advanced Solid Tumors, Prostate Cancer, Advanced Urothelial Carcinoma
- BL-M07D1Phase 317 trials
Sichuan Baili Pharmaceutical Co., Ltd. · HER2-positive Breast Cancer, Non-squamous Non-small Cell Lung Cancer, Her2-positive/Low-expression Urinary and Digestive Tract Tumors
- HS-20093Ris-Rez, Risvutatug rezetecanPhase 316 trials
Hansoh BioMedical R&D Company · Neoplasms, Lung, Sarcoma, Osteosarcoma
- Telisotuzumab AdizutecanABBV-400Phase 316 trials
AbbVie · c-MET, Non-Squamous Non-Small Cell Lung Cancer, Metastatic Colorectal Cancer
- SG001enlonstobart, Enlonstobart will be administrated on a 14-day cyclePhase 315 trials
CSPC Megalith Biopharmaceutical Co.,Ltd. · HER2-positive Gastric Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
- SYS6010Phase 315 trials
CSPC Megalith Biopharmaceutical Co.,Ltd. · Non-Small Cell Lung Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
- VolrustomigMEDI5752Phase 313 trials
AstraZeneca · Gastric Cancer, Non-small Cell Lung Cancer, Biliary Tract Cancer
- PF-08634404SSGJ-707Phase 312 trials
Pfizer · Non-Small Cell Lung Cancer, Lung Neoplasms, Carcinoma, Non-Small-Cell Lung (NSCLC)
- ZimberelimabAB122, GS-0122Phase 312 trials
Gilead Sciences · Lung Cancer, Non Small Cell Lung Cancer, Nonsquamous Non Small Cell Lung Cancer
- FianlimabREGN3767Phase 311 trials
Regeneron · Melanoma, Non-small Cell Lung Cancer, Hepatocellular Carcinoma
- IfebemtinibIN10018, BI853520Phase 311 trials
InxMed (Shanghai) Co., Ltd. · Solid Tumor, NSCLC, Solid Tumor Cancer
- Savolitinibhmpl-504, AZD6094Phase 311 trials
AstraZeneca · Carcinoma, Non-small Cell Lung Cancer, Non-Small Cell Lung Cancer
- TiragolumabMTIG7192A, RO7092284Phase 311 trials
Roche (Genentech) · Hepatocellular Carcinoma, Rectal Neoplasms, Rectal Cancer
- TQB2102Phase 311 trials
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · Breast Cancer, HER2-positive Breast Cancer, Gynecological Tumors
More on non-small cell lung cancer: recruiting trials · published research
Related in oncology: Breast cancer · Small cell lung cancer · Prostate cancer · Colorectal cancer · Melanoma · Ovarian cancer · Pancreatic cancer · Bladder and urothelial cancer · Kidney cancer (renal cell carcinoma) · Liver cancer (hepatocellular carcinoma)
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.